Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SABS vs PLUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SABS Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

SABS Overall Winner 6-Pillar Tally: SABS 3 – 2 PLUR (1 Tie) Matrix Metrics: SABS 6 – 3 PLUR

As of Nov 17, 2026, SAB Biotherapeutics, Inc. (SABS) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SABS carries a Unified Composite Score of 32.4/100 (SELL) at $2.92 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).

  • Growth vs. Quality Trade-Off: SABS earns the overall head-to-head edge with a stronger Unified Composite Score (32.4/100 SELL vs. PLUR 28.8/100 SELL) and 1.28β · 76% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although SABS compares more favorably head-to-head, both SABS (32.4/100 SELL) and PLUR (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: SABS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.8); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SABS vs PLUR
SABS NASDAQ Head-to-Head Winner
SAB Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.92
-2.83% 1D
Market Cap $266.7M
TTM Revenue $114,698
Forward P/E N/M
Beta / 30D Vol 1.28β · 76% Vol
Unified Composite Score
32.4 / 100 SELL
Tech 15.0 Fund 40.0 Flow 63.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 45
RSI-14: 44.8 · SMA20: $3.06 · SMA50: $3.09
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (SABS 3 – 2 PLUR)

Columns: Metric · SABS · PLUR
1. Valuation Multiples PLUR
Forward P/E N/M 3.6x
Trailing P/E N/M 3.6x
PEG Ratio N/M N/M
EV / Revenue N/M 44.6x
2. Growth & Scale PLUR
Revenue Growth (YoY) -62.4% -15.8%
Earnings Growth (YoY) -60.0% +0.0%
TTM Revenue (USD) $114,698 $1.0M
Market Cap $266.7M $15.1M
3. Profitability & Quality SABS
Gross Margin N/A 44.6%
Operating Margin 0.0% -2454.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -42.8% -1022.0%
4. Balance Sheet & Cash Flow SABS
Cash Generation (TTM) -$59M -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.5M Net Cash $30M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SABS
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 101.1% (17th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SABS (6) vs PLUR (3)
Institutional Metric SABS PLUR Criterion Row Edge
Market Capitalization
Scale
$266.7M $15.1M Larger Scale SABS
Trailing P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Forward P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-62.4% -15.8% Higher Growth PLUR
Operating Margin (TTM)
Profitability
0.0% -2454.5% Higher Margin SABS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-42.8% -1022.0% Higher ROE SABS
52-Week Range Position
Momentum
18% ($2–$5) 2% ($1–$5) Stronger Trend SABS
Beta / 30D Volatility
Risk Regime
1.28β · 76% Vol 0.80β · 102% Vol Lower Realized Risk SABS
Unified Institutional Score
Composite Signal
32.4 / 100 (SELL) 28.8 / 100 (SELL) Higher Composite SABS
Trailing 12M Revenue (USD)
Operating Scale
$114,698 $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 44.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59M ($9.5M Net Cash) -$22M ($30M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SABS +1.03 pp
SABS: +12.12% · PLUR: +11.09%
3M Horizon SABS +23.46 pp
SABS: -22.88% · PLUR: -46.34%
6M Horizon SABS +44.63 pp
SABS: -17.89% · PLUR: -62.52%
1Y Horizon SABS +65.5 pp
SABS: -10.03% · PLUR: -75.53%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SABS Revenue PLUR Revenue SABS Op. Margin PLUR Op. Margin Margin Leader
FY2019 N/A $0M N/A -65800.0% PLUR
FY2020 $60M $0M 37.2% -128156.5% SABS
FY2021 $60M N/A -22.0% N/A SABS
FY2022 $20M $0M -121.0% -17774.8% SABS
FY2023 $0M $0M -1700.6% -9493.4% SABS
FY2024 $0M $0M -3244.9% -6796.9% SABS
FY2025 N/A $0M N/A -1659.9% PLUR
FY2026 N/A $0M N/A -2454.5% PLUR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SABS SURGE
12d in phase · OBV DISTRIBUTION
Current IV 101.1%
IV Percentile 17th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SABS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SABS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $266.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SABS vs PLUR Key Questions & Quantitative Answers

As of Nov 17, 2026, SAB Biotherapeutics, Inc. (SABS) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SABS carries a Unified Composite Score of 32.4/100 (SELL) at $2.92 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Growth vs. Quality Trade-Off: SABS earns the overall head-to-head edge with a stronger Unified Composite Score (32.4/100 SELL vs. PLUR 28.8/100 SELL) and 1.28β · 76% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although SABS compares more favorably head-to-head, both SABS (32.4/100 SELL) and PLUR (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SABS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.8); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLUR leads the Growth & Scale pillar: SABS posts -62.4% YoY revenue growth and -60.0% YoY earnings growth on $114,698 TTM revenue (N/A gross margin, 0.0% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SABS cumulative revenue shifted -66.7% while PLUR shifted N/A. In operating R&D and SG&A reinvestment, SABS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.

PLUR screens cheaper on headline valuation multiples. SABS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SABS (-42.8% ROE) versus PLUR (-1022.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SABS carries 101.1% implied volatility (17th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.28β · 76% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.